ArticleBMC pulmonary medicine2025
Is folic acid associated with lung cancer development? A cross-sectional study in NHANES.
Article in BMC pulmonary medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveThe folic acid is used as an adjuvant dietary supplement in cancer treatment, but its potential benefits or adverse effects in lung cancer (LC) management remain unclear. This study aimed to examine the relationship between different forms of folic acid and LC based on a national population-based survey and conduct a thorough analysis of the potential use of folic acid in cancer treatment.
methodsCross-sectional analysis from the 2007-2018 National Health and Nutrition Examination Survey (NHANES) was assessed. A cohort of 27,631 participants was identified and weighted. Information on folic acid levels and malignancy was determined through laboratory tests and interviews. To address potential confounding variables, a 1:2 propensity score matching (PSM) was employed, and 201 participants were included. This study utilized restricted cubic splines (RCS) to explore the none-linear relationship between various forms of folic acid and the incidence of LC.
resultsSignificant associations were observed between clinical characteristics of the participants and LC in both unweighted and weighted analyses. Following PSM, total folate, dietary folate, 5-formyltetrahydrofolate (5-formylTHF) and 5,10-methylenetetrahydrofolate (5,10-methenylTHF) were significantly associated with LC risk (p < 0.05). The RCS analysis suggested that there was a significant non-linear association between 5,10-methenylTHF and the odds of developing LC. Additionally, total folate, folic acid, 5,10-methenylTHF, and RBC folate influenced the likelihood of developing LC in a certain dose range.
conclusionsThe development of LC was associated with total folate, dietary folate, 5-formylTHF and 5,10-methenylTHF levels. Folic acid, total folate, 5,10-methenylTHF, and RBC folate were positively correlated with LC within a certain range.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.